Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
27 hedge funds and large institutions have $10.9M invested in Carisma Therapeutics in 2018 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 7 closing their positions.
103% more capital invested
Capital invested by funds: $5.39M → $10.9M (+$5.56M)
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
17% more funds holding
Funds holding: 23 → 27 (+4)
0.18% more ownership
Funds ownership: 1.04% → 1.22% (+0.18%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $63K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$1.53M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.18M |
| 3 |
KCM
Kingdon Capital Management
New York
|
+$1.16M |
| 4 |
Millennium Management
New York
|
+$235K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$366K |
| 2 |
MERSOM
Municipal Employees' Retirement System of Michigan
Lansing,
Michigan
|
-$196K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$53K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$53K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$13K |
CARM Hedge Fund Activity: Q1 2018 in Review
27 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q1 2018, worth a combined $10.9M — up 103% from $5.39M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CARM positions and 7 closed out — a net gain of 4 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Highbridge Capital Management, opening a new position worth an estimated $1.53M. The largest seller was Virtu Financial, cutting an estimated $366K.
- 27 institutional investors held Carisma Therapeutics (CARM) as of Q1 2018, up from 23 in Q4 2017.
- Funds reported $10.9M of Carisma Therapeutics stock for Q1 2018, up 103% quarter-over-quarter.
- 11 funds opened new Carisma Therapeutics positions in Q1 2018 and 7 closed out, a net change of +4 holders.
- The largest Carisma Therapeutics buyer in Q1 2018 was Highbridge Capital Management, an estimated $1.53M added.
- The largest Carisma Therapeutics seller in Q1 2018 was Virtu Financial, an estimated $366K sold.
Based on aggregated 13F filings for Q1 2018.